Approved for use through 19/31/2012. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OME control number.

Substit	ute for fo	m 1449/PT	o	Co	mplete if known	
	INFORMATION PAGE COMP			Application Number	10/776,649	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 10, 2004		
STA			First Named Inventor	Hanson		
			•	Art Unit	1644	
(use	as many	/ sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	1	of	18	Attorney Docket Number	ABX-PF1 DIV2	•

Examples	Cite	Document Number	U.S. PATENT	T	
tribats"	Cita No.	Number - Kind Code <sup>2</sup> (if known)	MIN-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
IO_		RE 35,500	05/16/1997	Rhodes	
		6,255,458	07/03/2001	Lonberg et al.	7
		6,207,156	03/27/2001	Kuchroo et al.	/
		6,162,963	12/19/2000	Kucherlapati et al.	/
		6,150,584	11/21/2002	Kucherlapati et al.	/
		6,114,598	09/05/2000	Kucherlapati et al.	/
		6,075,181	06/13/2000	Kucherlapati et al.	/
		6,051,227	04/18/2000	Allison et al.	
		5,977,318	11/02/1999	Linsley etal.	
		5,968,510	10/19/1999	Linsley et al.	
		5,939,598	08/17/1999	Kucherlapati et al.	/
		5,916,771	06/29/1999	Hori et al.	
		5,855,887	01/05/1999	Allison et al.	
		5,827,690	10/27/1998	Meade et al.	
		5,814,318	09/29/1998	Lonberg et al.	
		5,811,097	09/22/1998	Allison et al.	
		5,789,650	08/04/1998	Lonberg et al.	
		5,789,215	08/04/1998	Berns et al.	/
		5,777,085	07/07/1998	Co et al.	/
		5,773,253	06/30/1998	Linsley et al.	
(0)		5,770,429	06/23/1998	Lonberg et al.	

xaminer			والمناوي بارزاي المسالة بدانتها		
Adi (m) Ei		1 4 . 1 0: 0	Date	01-	100
ignature	I d'A i Oa	MASKE MIN	Considered	9157	1101
		1/1/2//2///2/P-1/-V// WA'	COMPIGNION	11011	1100

"EXAMINER: hills if reference considered, whether or not clission is in conformance with MPEP 603. Draw the through dission if not in conformance and not considered, include copy of this form with need communication to applicant's unique clisten designation number (optional). 2 See Kinds Codes of USPTO Patient Documents of www.spiz.gov or MPEP 901.04, 3 Enter Office that issued the document, by the involation code (WIPO Standard ST.3). 4 For departed spiral documents, the indication of the year of the length of the Emparer must precede the sents number of the patient document. 3 Kind of document by the appropriate symbols as indicated on the occurrent under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English Enguago Transistion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to corrulete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commente, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Tracement Office: U.S. DEPARTMENT OF COMMERCE
Control number

U.S. Patent and Tracement Office: U.S. DEPARTMENT OF COMMERCE
Control number

Substit	ute for fo	m 1449/P1	o	Con	plete if known	
	INFORMATION DISCLOSURE			Application Number	10/776,649	
				Filing Date	February 10, 2004	
STA	STATEMENT BY APPLICANT		First Named Inventor	Hanson		
			•	Art Unit	1644	
(use	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	Sheet 2 of		18	Attorney Docket Number	ABX-PF1 DIV2	

		U.S. PATENT	DOCUMENTS	
10	5,770,197	06/23/1998	Linsley et al.	
	5,756,687	05/26/1998	Denman et al.	
	5,750,172	05/12/1998	Meade et al.	·
	5,741,957	04/21/1998	Deboer et al.	
	5,733,743	03/31/1998	Johnson et al.	
	5,721,367	02/24/1998	Kay et al.	
	5,714,350	02/03/1998	Co et al.	
	5,703,057	12/30/1997	Johnston et al.	
	5,697,902	12/16/1997	Godenberg	
	5,693,792	12/02/1997	Torii et al.	
	5,693,761	12/02/1997	Queen et al.	
	5,661,016	08/26/1997	Lonberg et al.	·
	5,648,471	07/15/1997	Burram et al.	
	5,643,763	07/01/1997	Dunn et al.	
	5,633,425	05/27/1997	Lonberg et al	
	5,625,126	04/29/1997	Lonberg et al.	
	5,612,205	03/18/1997	Kay et al.	
	5,591,669	01/07/1997	Krimpenfort et al.	
	5,585,089	12/17/1996	Queen et al.	
	5,569,825	10/29/1996	Lonberg et al	
	5,545,807	08/13/1996	Surani et al.	
ID	5,545,806	08/13/1996	Lonberg et al.	

Examiner Signature	Trion	auber Mi	Date Considered	a7	27/06
			1 00113100180		

\*EXAMINER: Intelle If reference considered, whicher or nox clusion is in conformence with MPEP 809. Draw line through cluston if not in conformence and not considered, include copy of this form with next communication to applicant, it Applicant's undoug cluston designation number (optional). 2 Ease Kinds Codes of USPTO Parant Decuments at www.uspto.gov of MPEP 801.04. 3 Enter Office that issued the document, by the involution code (WIPO Standard ST.3). 4 For departure parant potential, the indication of the year of the rough of the Empirer must precede the sortal number of the parant document. 5 Kind of document by the appropriate symbols as indicated on the document which will possible. 8 Applicant is to place a check mark here if English tanguage Yarastallion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or remin a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent in the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Tradsmark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB

Substit	ute for for	m 1449/P7	o.	Сол	plete if known	
				Application Number	10/776,649	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 10, 2004			
		First Named Inventor	Hanson			
			,	Art Unit	1844	
(use	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	3	of	18	Attorney Docket Number	ABX-PF1 DIV2	

		U.S. PATENT	DOCUMENTS	
10	5,530,101	06/25/1996	Queen et al.	
	5,434,131	07/18/1995	Linsley et al.	/
	5,194,594	03/16/1993	Khawli et al.	
	5,151,510	09/29/1992	Stec et al.	/
	5,102,990	04/07/1992	Rhodes	/
	5,101,827	04/07/1992	Goldenberg	
	4,959,455	09/25/1990	Clark et al.	/
	4,912,040	03/27/1990	Kaufman et al.	
	4,816,397	03/28/1989	Boss et al.	
	4,740,461	04/26/1988	Kaufman	/
	4,735,210	04/05/1988	Goldenberg	
	4,683,202	07/28/1987	Mullis	
	4,683,195	07/28/1982	Mullis et al.	
	4,681,581	07/21/1987	Coates	
	4,399,216	08/16/1983	Axel et al.	<del>  /                                   </del>
	2002/0086014	07/04/2002	Korman et al.	1/

		FO	REIGN PATEN	T DOCUMENTS		
Examinar	Cite	Foreign Patent Document	Publication Date		Pages, Columns, Linea, Where Resevent	
elst n		MM-DD-YYYY	Country	Passages or Relevant	74	
		CA 2,205,680	11/16/1998	Canada		_
10		EP 0 546 073	06/16/1993	Burope		

Signature Tion	Misselfiller	Date Considered	9	127/	105
----------------	--------------	--------------------	---	------	-----

EXAMINER: Initial if reference considered, whether or not cleans is in conformance with MPEP 669. Draw line through cleation if not in conformance and not considered, include copy of this form with next communication to applicant, it Applicant's unique deation designation number (optional), 2 See Kinds Codes of USPTO Peters Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-teter code (NPPO Standard ST.3). 4 For Japanese palant documents, the molecular of the party of the Emperor must proceed the sansi number of the patent document. 5 Kine of document by the appropriate symbols as indicated on the goodman under WIPO Standard ST.18 If possible. 8 Applicant is to piace a check mark here if English language Transistion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any convients on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. CMB 0051-0031
U.S. Palent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons one required to respect to a collection of information unless it contains a valid Caris control number.

Substit	ute for for	m 1449/P1	Ō	Con	plete if known	
				Application Number	10/776,649	
INFORMATION DISCLOSURE		CLOSURE	Filing Date	February 10, 2004		
STA	STATEMENT BY APPLICANT		First Named Inventor	Hanson		
			,	Art Unit	1644	
(use	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	4	of	18	Attorney Docket Number	ABX-PF1 DIV2	

		FOREIGN PATEN	T DOCUMENTS		
I()	EP 0 463 151	01/02/1992	Europe		
	EP 0 338 841	10/25/1989	Europe		/
	EP 0 323 997	07/19/1989	Europe		
	EP 0 256 055	02/24/1998	Europe		/
	EP 0 239 400	08/03/1994	Europe		
	EP 0 216 846	04/08/1987	Europe		
	WO 01/14424	03/01/2001	PCT		
	WO 00/32231	06/08/2000	PCT		
	WO 98/50433	11/12/1998	PCT		
	WO 98/46996	10/22/1998	PCT	/	
	WO 98/42752	10/01/1998	PCT		
	WO 98/24893	06/11/1998	PCT		
	WO 98/24884	06/11/1998	PCT		
	WO 97/38137	10/16/1997	PCT	/	
	WO 97/20574	06/12/1997	PCT		
	WO 97/13852	04/17/1997	PCT		
	WO 96/34096	10/31/1996	PCT		
	WO 96/33735	10/31/1996	PCT	1 / .	
	WO 96/22380	07/25/1996	PCT	/	
	WO 96/14436	05/17/1996	PCT		
	WO 95/33770	12/14/1995	PCT	1/	
10	WO 95/24217	09/14/1995	PCT		

Examiner	17.		- 4: 1		Date	N		
Signature	I JA I OA	1.15 1	DALL S	1.1		4/	ソフノ	06
		-1:/:///	XIO CIC	Χ <i>I.Δ</i>	Considered	<u></u>	211	(1/2)

\*EXAMINER: Initial if reference considered, whether or not closion is in conformance with MPEP 609. Draw line through claster if not in conformance and not considered, include copy of the form with next communication to explicant; in Applicant's unique closion designation number (optional). 2 See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-later code (WIPO Sandard ST.3). 4 For Japanese patient documents, the moreation of the year of the retign of the Emparty must precede the sense number of the pasent document. 5 Kind of document by the appropriate symbols as incicated on the document under WIPO Standard ST.18 of possible. 6 Applicant is place a check mark here if English tampuage Translation is asserted.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CfR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. 8END TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. CMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1885, no persons are required to respond to a collection of information unless it contains a valid CA/B

Substit	ute for for	n 1449/PT	o o	Complete if known		
				Application Number	10/776,649	
INF	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	February 10, 2004	
STA				First Named Inventor	Hanson	
				Art Unit	1644	
(use	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	5	of	18	Attorney Docket Number	ABX-PF1 DIV2	

		FOREIGN PATEN	IT DOCUMENTS	
IO	WO 95/03408	02/02/1995	PCT	
	WO 95/01994	01/19/1995	PCT	/-
	WO 94/29444	12/22/1994	PCT	
	WO 94/25585	11/10/1994	PCT	/
	WO 94/02602	02/03/1994	PCT	
	WO 94/00569	01/06/1994	PCT	
	WO 93/12227	06/24/1993	PCT	//
	WO 93/00431	01/07/1993	PCT	
	WO 92/22670	12/23/1992	PCT	
	WO 92/22647	12/23/1992	PCT	
	WO 92/22645	12/23/1992	PCT	
	WO 92/03918	03/19/1992	PCT	
	WO 91/10741	07/25/1991	PCT	

		NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cite No.1	Moude name of the suctor (in CAPITAL LETTERS), title of the entice (when appropriate), title of the item (book, megazine, journal, sensil, symposium, cotolog, etc.), date, page(s), volumeissus number(s), publisher, dity and-or country where published	74
		Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells,: J. Immunol., 157:4762-4770 (1996)	
		Allison & Krummel, "The Yin and Yang of T cell costimulation, "Science, 270:932-933 (1995)	
10		Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," Int.  J. Cancer. Supplement, 7:28-32 (1992)	

Examiner	7/0-	(1.000	/ Oate	Λ	15-1	25
Signature	Via		(A) Considered	9/	1211	115

"EXAMINER: Initial of reference considered, whether or not createn is in conformance with MPEP 609. Draw line tutrough catason if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique disting designation number (appendix). 2 See Minds Codes of USPTO Palant Decuments at www.uspto.gov or MPEP 301.04, 3 Enter Office after issued the adocument, by the healthfor code (MIPO Standard ST.3). 4 For Apparence patient documents, the increation of the stept of the Emperor must precede the selfur number of the parent recurrent. 5 Mins of documents by the appropriate symbols as indicated on the occurrent winder WIPO Standard ST.16 if possible. 8 Applicant to place a check many near if English (English) English is station is sitsched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Approved for use through 10/31/2002, OMB 0851-0031

U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paparwork Reduction Act of 1995, no parsons are required to respond to a collection of information unless it contains a valid CMB

Substit	ute for for	m 1449/P7	О	Complete if known			
				Application Number	10/776,649		
INF	DRMAT	ion dis	CLOSURE	Filing Date	February 10, 2004		
STA	STATEMENT BY APPLICANT			First Named Inventor	Hanson		
				Art Unit	1644		
(use	(use as many sheets as necessary)		Examiner Name	Ilia I. Ouspenski			
Sheet	6	of	18	Attorney Docket Number	ABX-PF1 DIV2		

******	NON PATENT LITERATURE DOCUMENTS	
OL	Barker and Dayhoff, "Detecting distant relationships: computer methods and results," Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)	•
	Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X <sub>L</sub> induction," J Immunol, 160:12-15 (1998)	
	Blake and Litzi-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," Bioconjugate Chem., 3:510-513 (1992)	
	Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," Proc Natl Acad Sci USA, 90:11059-11063 (1993)	
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," Science, 253:164-170 (1991)	•
	Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," PNAS USA, 86:6709-6713 (1989)	-
	Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," Methods: A companion to Methods in Enzymology, 2:159-165 (1991)	
	Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," Eur. J. Immunol., 21:1323-1326 (1991)	
	Bruggemann and Neuberger, "Strategies for expressing human antibody repertoires in transgenic mice," Immunology Today, 17:391-397 (1996)	
	Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4,"  Nature, 328:267-270 (1987)	
	Bumpers et al., "Consistent hopatic metastasis of human colorectal cancer in severe combined immunodeficient mice," J. Surgical Res., 61:282-288 (1996)	
10 T	Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," Immunology, 90:265-271 (1997)	

Examiner	100		O i O Date	1	100	-
Signature	5 / A OA	11/1/1/10	//	1 09	177/11/	
Name and Address of the Owner, where the Owner, which is the Owner, where the Owner, which is the Owner, where the Owner, which is the Ow	47/1/21		LAZXIA CONSIL	dered	<u>~</u> 11 00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw fine through crackon if not in conformance and not considered, include copy of this form with next concrutication to applicant. 1 Applicant's unique diation essignation number (oppose). 2 See Kinds Coces of USPTO Patent Documents at www.usquo.gov.or MPEP 901.04. 3 Enter Office that issued the document, by the two-leater code (MIPO Glandard ST.3). 4 For Japanese patent documents the year of the Fireperor must precede the earlal number of the patent document. 5 Kind of goodment by the appropriate symbols as indicated on the colument under VIPO Standard ST.16 if possible. 6 Applicant is to place a crack mark here if English language Transistion is exacted.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002, OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMA control number.

Substit	ute for for	n 1449/PT	0	Complete if known				
	•			Application Number	10/776,649			
INF	DRMATI	on disc	CLOSURE	Filing Date	February 10, 2004			
STA	STATEMENT BY APPLICANT			First Named Inventor	Hanson	***************************************		
	•		. 2.0	Art Unit	1644			
(นธ	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski			
Sheet	7	of	18	Attorney Docket Number	ABX-PF1 DIV2			

	NON PATENT LITERATURE DOCUMENTS	
TO	Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," Cell, 71:1093-1102 (1992)	
	Chen et al. "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the J <sub>H</sub> locus," International Immunology, 5:647-656 (1993)	
	Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," Human Gene Therapy, 5:595-601 (1994)	
	Chiswell and McCafferty, "Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?" TIBTECH, 10:80-84 (1992)	
	Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," Nature Genetics, 4:117-123 (1993)	
	Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," J. Mol. Biol., 196:901-917 (1987)	
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," Nature, 342:877-883 (1989)	
	Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," J. Immunol., 159:144-151 (1997)	-
	Coligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," Current Protocols in Immunology, 2.1.1-2.1.22 (1994)	
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," PNAS USA, 87:6378-6382 (1990)	
10	Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," Eur. J. Immunol., 18:1901-1905 (1988)	

-					
Examiner Signature	do-	the exact st.	Date	0/27/00	
Signame	2100	Under July	Considered	3/2//105	
			- CONCOCCO		

\*EXAMINER: Initial if reference considered, whether or not district is in conformance with MPEP 809. Draw line through district in conformance and not considered, include copy of this form with next conformation to applicant, if Applicant's unique district designation number (optional), if 2 see Kinda Codes of USPTO Patient Documents at www.uspro.gov or MPEP 901.04. If Enter Office that issued the document, by the No-latter code (WIPO Standard 87.3). If For Japanese patient documents, the indication of the year of the reign of the Emperor must precode the serial number of the pating occurrent. Signal of document by the appropriate symbols as Indicated on the document under WIPO Standard 97.16 if possible. 6 Applicant is to place a check mark here if English language Transistion is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) as application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this borden, should be sent to the Chief Information Officer, U.S. Paleat and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionar for Partents. P.O. Box 1450, Alexandria VA 22313-1450. for Petents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

2125969325

Substit	ute for for	n 1449/PT	O	Complete if known		
				Application Number	10/776,649	
INF	ORMATI	ON DIS	CLOSURE	Filing Date	February 10, 2004	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Hanson	***************************************
				Art Unit	1644	
(use	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	8	of	18	Attorney Docket Number	ABX-PF1 DIV2	

	NON PATENT LITERATURE DOCUMENTS	
TO	Dayhoff, "Survey of new data and computer methods of analysis," Atlas of Protein Sequence and Structure, pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))	
	de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," Eur J Immunol, 23:3120-3125 (1993)	
	Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," J. Med. Chem., 30:1229-1239 (1987)	
	Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," J Exp Med, 188:205-210 (1998)	
	Fanger et al., "Production and use of anti-FcR bispecific antibodies,"  ImmunoMethods, 4:72-81 (1994)	
	Fauchere, "Elements for the rational design of peptide drugs," Adv. Drug Res., 15:29-69 (1986)	
	Fishwild et al., "High-avidity human IgGr: monoclonal antibodies from a novel strain of minilocus transgenic mice," Nature Biotech., 14:845-851 (1996)	
	Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM' B Cells," J. Clin. Invest.: 99, No. 7:1614-1627 (1997)	
	Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," J Exp Med., 178:2185-2192 (1993)	•
	Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," Science, 262:907-909 (1993)	
IO	Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," J Immunol, 161:2708-2715 (1998)	

Examiner Signature	Thin	Charles Date Considered	9/2	7/05
-----------------------	------	-------------------------	-----	------

"EXAMINER: Initial it reference considered, whether or not estation is in conformance with MPEP 606, Draw into tribuigh crision if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicants unique distinct designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspta.gov or MPEP 901.04. 3 Enter Office our issued the occurrent, by the two-letter code (WIPO Standard ST.3). 4 For Applicant occurrents, the indication of the year of the impairer must precede the serial number of the patent cocurrent. 5 Kind of document by the propriorate symbols as indicated on the document under WIPO Standard ST.16 of possible. 6 Applicant is to place a check mark here if English language Translation is standard.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for vary depending open the individual case. Part continues on the annual of the property of the continues of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Palents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contrains a valid OMB contra number.

Substitu	ute for form	1449/PT	0	Con	plete if known	
				Application Number	10/776,649	
INFO	DRMATIO	N DIS	CLOSURE	Filing Date	February 10, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Hanson	
				Art Unit	1644	
(use	as many s	neets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	9	of	18	Attorney Docket Number	ABX-PF1 DIV2	

	NON PATENT LITERATURE DOCUMENTS	
70	Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," Proc Nat'l Acad Sci USA, 95:12022-12027 (1998)	
	Furet et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," Journal of Computer-Aided Molecular Design, 9:465-472 (1995)	
	Galfre and Milstein, "Preparation of monoclonal antibodies: strategies and procedures." Methods Enzymol., 73:3-46 (1981)	
	Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," Acia Biochimica Polonica, 44:557-564 (1997)	
	Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," Proc Nat'l Acad Sci USA, 79:6777-6781 (1982)	
	Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," J. Exp. Med., 188:483-495 (1998)	
	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," Nature Genetics, 7:13-21 (1994)	
	Gribben et al., "CTLA4 mediates antigen-specific apoptosis of human T cells,"  Proc. Natl. Acad. Sci., 92:811-815 (1995)	
	Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," Cell, 41:885-897(1985)	
	Hanes and Plückthun, "In vitro selection and evolution of functional proteins by using ribosome display," Proc Nat'l Acad Sci USA, 94:4937-4942 (1997)	
70	Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," Nature, 356:607-609 (1992)	

Examiner Signature	Thia	Chipping.	Date Considered	9/27	105

\*EXAMINER: Initial of reference considered, whether or not cliation is in conformance with MPEP 609, Draw line through distion of not an conformance and not considered, include copy of this form with next communication to applicant. I Applicant's unique discon designation number (optional). I see Minds Codes of USPTO Patent Documents at whether code of WPPO Standard ST.3). I for departue gotten occurrent, the institution of the year of the improvements of the patent document. S Mind of document by the appropriate symmetric are indicated on the cogment under WIPO Standard ST.18 if possible. 6 Applicant is to place a drack mark here if English tanguage Translation is pictoched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require the complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	rte for form	1449/PT	<b>O</b> .	Con	plete if known	
				Application Number	10/776,649	
INFO	PRMATIC	N DIS	CLOSURE	Filing Date	February 10, 2004	
			PLICANT	First Named Inventor	Hanson	
•	* ****	901 740	1 2,0,411	Art Unit	1644	
(use	as many s	heets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	10	of	18	Attorney Docket Number	ABX-PF1 DIV2	

		NON PATENT LITERATURE DOCUMENTS	
Ţ	)	Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," J Immunol, 147:1037-1044 (1991)	
		Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science, 262:905-907 (1993)	
		Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," J Mol Biol, 282:195-208 (1998)	
		Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," PNAS USA 90:6444-6448 (1993)	
		Hoogenboom et al., "Building antibodies from their genes," Immunol. Reviews, 130:43-68 (1992)	
		Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," J Immunol, 160:2706-2714 (1998)	
		Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," BioTechniques, 13:412-421 (1992)	
		Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," Proc Nat'l Acad Sci USA, 82:5131-5135 (1985)	·
		Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," J Neuroimmunol, 73:57-62 (1997)	
		Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," Proc Natl Acad Sci USA, 95:10067-10071 (1998)	1
1	D 0	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," Protein Engineering, 10:949-957 (1997)	

Examiner Signature	Thin	auber	Date Considered	9/27/05

TEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line strongly ottation if not in conformance are not considered. Include copy of this form with next communication to applicant. I Applicant's unique disting designation number (options). 2 See Nints Codes of USPTO Parent Documents at www.uspts.gov or NIPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (NIPO Standard ST2). 4 For Japanese potent occuments, the hadication of the pear of the reign of the Emperor must precede the serial number of the pattern document. 5 Nint of document by the appropriate symbols as inclusived on the document under WIPO Standard ST.16 ii possible. 8 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002, OMB 0851-0031 5. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMER(	ĴΕ
Under the Paperwork Reduction Act of 1995, no per	so bilav a salaman a sculru noitermaini in noiteana a at broquer or beniver era anos	A.E
control number.	, , , , , , , , , , , , , , , , , , , ,	

Substitu	ute for form	1449/PT	0	Con	nplete if known	
				Application Number	10/776,649	
INF	DRMATIO	N DISC	CLOSURE	Filing Date	February 10, 2004	
STA	TEMENT	BY AF	PLICANT	First Named Inventor	Hanson	
				Art Unit	1644	
(use	as many si	neets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	13	of	18	Attorney Docket Number	ABX-PF1 DIV2	

	NON PATENT LITERATURE DOCUMENTS
JO	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome." Nature, 362:255-258 (1993)
	Jakobovits et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-coll development and antibody production." <i>Proc. Natl. Acad. Sci. USA</i> , 90:2551-2555 (1993)
	Jakobovits, "Humanizing the mouse genome." Current Biology, 4:761-763 (1994)
	Jakobovits, "Production of fully human antibodies by transgenic mice." Current Opinion in Biotechnology, 6:561-566 (1995)
	Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," Expert Opinion on Investigational Drugs, 7:607-614 (1998)
	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 321:522-525 (1986).
	Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," Biochem J, 322:927-935 (1997)
	Junghans et al. in Cancer Chemotherapy and Biotherapy, 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))
	Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," J. Immunol., 148:1547-1553 (1992)
	Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," J Exp Med. 182:459-465 (1995)
10	Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," Int Immunol, 8:519-523 (1996)

Examiner	T Dc		Date	0/2-1	00
Signature	100	[ A & Inglish	(a) Considered	4/27/	Uh

"EXAMINER: this if reference considered, whether or not citation is in conformance with MPEP 609. Draw line straigh dispon if not in conformance and not considered include copy of this form with next communication to applicant. I Applicant's unique distinct designation number (optional). 2 See [Anas Codes of USPTO Patient Occurrent, by the workest code (WIPO Standard ST.3), 4 For Japanese parent document, the undestine of the year of the religion of the Emperor must precede the sound number of the potent occurrent. 5 [And of document by the appropriate symbols as indicated on the occurrent under WIPO Standard ST.18 II possible. 6 Applicant is to place a check mark here if English tanguage Transistion is stracted.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 bours to complete, including gathering, preparing, and submitting the complete dapplication form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademurk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Officer. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

Substit	te for form 14	49/PT	<b>O</b> -	Complete if known		
				Application Number	10/778,649	
INFO	DRMATION	DISC	CLOSURE	Filing Date	February 10, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Hanson	
J	.,,_,,_,,			Art Unit	1644	
(use as many sheets as necessary)				Examiner Name	Ilia I. Ouspenski	
Sheet	12	of	18	Attorney Docket Number	ABX-PF1 DIV2	

		NON PATENT LITERATURE DOCUMENTS	
I	0	Kuohroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," Cell, 80:707-718 (1995)	
		Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," Pro Nat'l Acad Sci USA, 94:8099-80103 (1997)	
		LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III  NMR and UV spectroscopic studies of the R <sub>p</sub> -R <sub>p</sub> , S <sub>p</sub> -S <sub>p</sub> duploxes. [d(GG <sub>4</sub> AATTCC)] <sub>2</sub> , derived from diastereomeric O-ethyl phosphorothioates," Nucl.  Acids Res., 14:9081-9093 (1986)	
		Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," Proc Nat'l Acad Sci USA, 90:11054-11058 (1993)	
		Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," Science, 257:789-792 (1992)	
		"Leucocycte Typing VI: White Cell Differentiation Antigens," Garland Publishing, New York, NY, pp 30-31, 95-98 and 1213-1214 (1998)	
		Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," J Exp Med, 188:199-204 (1998)	
		Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," J. Exp. Med., 174:561-569 (1991)	
		Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD-28 on activated T lymphocytes," J Exp Med, 176:1595-1604 (1992)	
		Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," Science, 257:792-795 (1992)	
1	0	Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fe-dependent biologic activity, J.Immunol., 139:3521-3526 (1987)	

Examiner Signature	Thio	anyperel	Date Considered	9/27/	05

\*EXAMINER: Install if reference considered, whether or not challen is in conformance with MPEP 609. Dow line through clission if not in conformance and not considered, include copy of this form with next communication to applicant, if Applicant's unique distinct designation number (opcores). 2 See Nords Codes of USPTO Patent Documents at www.uspro.gov of MPEP 601.04. 3 Enter Office that issued the occurrent, by the explication of NPEP 601.04. 3 Enter Office that issued the occurrent, by the buffer office of the region of the Emperor must precede the sensit number of the patent document. 5 Kind of document by the exprepation set indication on the occurrent white Standard ST.18 if possible. 8 Applicant is to place a check mark here if English tanguage Transiption is practiced.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for educing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Tradomerk Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1893, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitu	ite for form	1449/PT	0	Complete if known		
		• • • • • •		Application Number	10/776,849	
INFO	RMATIO	N DISC	CLOSURE	Filing Date	February 10, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Hanson	
				Art Unit	1644	
(use	as many si	neets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	13	of	18	Attorney Docket Number   ABX-PF1 DIV2		

	NON PATENT LITERATURE DOCUMENTS	
70	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," Proc Nat'l Acad Sci USA, 84:3439-3443 (1987)	
	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Nature, 368:856-859 (1994)	
	Luhder et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," J Exp Med, 187:427-432 (1998)	
	Mandal et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," Nature Biotechnology, 14:323-328 (1996)	
	Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," Gene Therapy, 4:11-15 (1997)	
	Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4," J Clin Invest, 101:2446-2455 (1998)	
	Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes." Eur. J. Immunol., 21:985-991 (1991)	
	Marrack et al., "The Staphylococcal Enterotoxins and Their Relatives," Science, 705-711 (1990)	
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," The EMBO Journal, 13:5303-5309 (1994)	
	McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," J Exp Med, 186:183-187 (1997)	
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," Nature Genetics, 15:146-156 (1997)	
IO	Monfardini et al. "Rational design, analysis, and potential utility of GM-CSF amagonists," Proc Assoc Am Physicians, 108:420-431 (1996)	

101. 10-
1 9/27/1/5
e

"EXAMINER: What if reference considered, whether or not citation to in conformance with MPSP 608. Draw time through citation if not in conformance and not considered include copy of this form with next contruction to expellent. 1 Applicants unique distinct of estimation number (collents). 2 See Ninos Codes of USPTO Patent Document . at www.USpro.gov or NPEP 901.04. 3 Erist Office that induced not document by the two-letter code (WIPO Standard ST.3). 4 For Jacanese patent occurrents, the Indication of the year of the religion of the Emperor must precede the sumber of the patent document. 5 Nind of document by the appropriate symbots as indicated on the document, and of document of the patent document.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

Approved for use through 10/31/2002. OMS 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a pollection of information unless 8 certains a valid OMB control number.

Substitu	ite for form	n 1449/PT	0	Complete if known		
Cobbatt	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	. , , , , , , , , ,	•	Application Number	10/776,649	
INE	SPMATI	ON DIS	CLOSURE	Filing Date	February 10, 2004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Hanson	
SIA	I EMEN	IPIM	PEIGNIT	Art Unit	1844	
ในธย	as manv	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski	
Sheet	14	of	18	Attorney Docket Number	ABX-PF1 DIV2	

	NON PATENT LITERATURE DOCUMENTS	
10	Morrison, "Transfectomas provide novel chimeric antibodies," Science, 229:1202-1207 (1985).	
	Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, Leishmania donovani," J. Immunol., 161:4153-4160 (1998)	
	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," Mol. Biol., 48:443-453 (1970)	
	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," Nature, 314:268-270 (1985).	
	Oi et al., "Chimeric antibodies," Biotechniques, 4(3):214-221 (1986).	
	Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," Mol. Cell. Bio., 3:280-289 (1983).	
	O'Kennedy et al., "Antibody engineering: an overview," Essays in Biochemistry, 46:59-75 (1991).	
	Parmley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," Gene, 73:305-318 (1988)	
	Parren, "Preparation of genetically engineered monoclonal antibodies for human immunotherapy," Human Antibodies and Hybridomas, 3:137-145 (1992).	•
	Pearson and Lipman, "Improved tools for biological sequence comparison,"  Proc. Natl. Acad. Sci. U.S.A., 85:2444-2448 (1988)	
	Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," Immunity, 6:411-417 (1997)	
10	Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," Immunol Res, 14:189-199 (1995)	

Examiner Signature	Tion	O(1) IOP[1] Date Considered	9/27/	05
			71	

EXAMINER: tridal if reference considered, whether or not distain is in conformance with IMPEP 608. Onsw line strough citation if not in conformance and not considered, whether or not distain is necessarily strated congruing marrier (optional). If fee Kines Codes at USPTO Patent Document is trewwaysto, gov or IMPEP 801,04. I Enter Office that issued the document, by the healest code (WIPO Standard ST.3). If For Japanese patent documents, inc strategion if the year of the target of the Emperor must precove the serial number of the patent document. If Kind of document by the appropriate symbols as indicated on the document, ander WIPO Standard ST.16 if possible. If Applicant is to place a check mark nere if English language Translation is standard.

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for roducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trudemark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionary

15

Sheet

18

of

PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0851-0031
U.S. Patent and Trademerk Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1898, no persons are required to respond to a collection of information unless it contains a valid OMB

ABX-PF1 DIV2

control number.			
Substitute for form 1449/PTO	Complete If known		
Odborge la latti 14 tot 10	Application Number	10/776,649	
INFORMATION DISCLOSURE	Filing Date	February 10, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Hanson	
STATEMENT OF AFFEIDATE	Art Unit	1644	
(use as many sheets as necessary)	Examiner Name	Ilia I. Ouspenski	

Attorney Docket Number

	NON PATENT LITERATURE DOCUMENTS	
9-	Perrin et al. "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis J Immunol, 157:1333-1336 (1996)	
	Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scauning synthetic peptide combinatorial libraries," Biotechniques, 13:901-905 (1992)	
	Powell et al., "Compendium of excipients for parenteral formulations," PDA J Pharm Sci Technol. 52:238-311 (1998)	
	Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," Proc Natl Acad Sci USA, 90:11182-11186 (1993)	
	Riechmann et al., "Reshaping human antibodies for therapy," Nature, 332:323-327 (1988).	
	Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructures," Annu. Rev. Biochem., 61:387-418 (1992)	
	Russel et al., "Retroviral vectors displaying functional antibody fragments,"  Nucl. Acids Research, 21:1081-1085 (1993)	
	Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," Cell, 71:1065-1068 (1992)	
	Scott, "Discovering peptide ligands using epitope libraries," Trends in Blochemical Sciences, 17:241-245 (1992)	<u> </u>
	Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," J Med Chem, 40:1130-1135 (1997)	
	Smith and Waterman, "Comparison of Biosequences," Adv. Appl. Math., 2:482-489 (1981)	
10	Songsivilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," Clin. Exp. Immunol., 79: 315-321 (1990)	

Examiner Signature	Then	Or Molfalla + Consider	dered 9	127/	105
			··· (		

"EXAMINER: Initial if reference considered, whether or not discion is in conformance with MPEP 609. Draw line through citation of not in conformance and not considered, include copy of this form with next communication to applicant. I Applicant's unique distinct designation number (optional), 2 See Winds Codes of USPTO Patient Occurrents in www.cspto.gov or MPEP 901,04. 3 Enter Office that issued the document, by the two-lotter code (MPO Standard ST.1). 4 For Japanese potent documents, the indication of the year of the relign of the Emperor must precede the seefal number of the patient document. 5 Kind of document by the appropriate symbols as indicated on the security under WIPO Standard ST.16 if possible. 6 Applicant is to piece a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or remain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will be completed to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will be completed application form to the USPTO. vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademsrk Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademsik Cities. On Delivers a valid OMB Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless 8 contains a valid OMB control number.

Substitu	te for form	1449/PT	0	Complete if known			
Jubouu		1 ( 7 7 6 7 1	•.	Application Number	10/776,649		
INE	TAMAT	ON DISC	CLOSURE	Filing Date	February 10, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Hanson		
314	LEMEN	) DI A	FLICATI	Art Unit	1644		
(use	as many	sheets as	necessary)	Examiner Name	Ilia I. Ouspenski		
Sheet	16	of	18	Attorney Docket Number	ABX-PF1 DIV2		

	NON PATENT LITERATURE DOCUMENTS	
IO	Stee et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothicate analogues of oligodeoxyribonucleotides," J. Am. Chem. Soc., 106:6077-6079 (1984)	
	Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," Nucl. Acids Res., 16:3209-3221 (1988)	
	Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," Nucleic Acids Research, 20:6287-6295 (1992)	
	Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"  International Immunology, 6:579-591 (1994)	
	Thornton et al., "Prediction of progress at last" Nature, 354:105-106 (1991)	
	Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," Immunity, 3:541-547 (1995)	
	Townsend and Allison, "Tumor rejection after direct costimulation of CD8 <sup>+</sup> T cells by B7-transfected melanoma cells," Science, 259:368-370 (1993)	
	Trannecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," EMBO J, 10:3655-3659 (1991)	•
	Traunecker et al., "Janusin: new molecular design for bispecific reagents," Int.  J. Cancer (Suppl.), 7:51-52 (1992)	
	Tuaillon et al., "Analysis of direct and inverted DJ <sub>H</sub> rearrangements in a human Ig heavy chain transgenic minilocus," J. Immunol., 154:6453-6465 (1995)	
	Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in μ and γ transcripts," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3720-3724 (1993)	<b></b>
10	Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," Chemical Reviews, 90:543-584 (1990)	

		The second second			-		كالمسترب المستنفسين
Examiner Signature	This.	Onesse	A.	Date Considered	9	127/	2005

\*EXAMINER: Initial if reference considered, whether or not obtain its in conformance with MPEP 609. Draw line drawing distinct if not in conformance and not considered, include copy of this form with next communication to applicant. I Applicant's unique distinct designation number (optional). 2 See Minds Codes of USPTO Pation Coopyrems at www.uspic.gov or MPEP 901.04. 3 Enter Office that its instead of the document by the two-lear code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the ridge of the Emperor must precede the security amphor of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

Approved for use through 10/31/2002, CMB 0861-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a walld CAUB

Subosite	ite for form	1440/PT	0	Complete if known			
Supsuit	16 101 101111	1770/1	•	Application Number	10/776,849		
INEC	DMATIC	N DISC	CLOSURE	Filing Date	February 10, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Hanson		
314	I EINEM I	DI A	PLIOAITI	Art Unit	1644		
(use	as many s	heets as	песеззагу)	Examiner Name	tila I. Ouspenski		
Sheet	17	of	18	Attorney Docket Number	ABX-PF1 DIV2		

NON PATENT LITERATURE DOCUMENTS						
JO	Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," The Journal of Experimental Medicine," 186, 1119-1128 (1997)					
	Vaswani et al., "Humanized antibodies as potential therapeutic drugs," Annals of Allergy, Asthma & Immunology, 81:105-119 (1998).					
	Veber and Freidinger, "The design of metabolically-stable peptide analogs,"  Trends In Neuro Sciences, pp. 392-396 (1985)					
	Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity," Science, 239:1534-1536 (1988).					
	Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," Immunol Today, 14:252-259 (1993)	_				
	Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," Immunity, 1:405-413 (1994)					
	Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," J Exp Med, 183:2541-2550 (1996)					
	Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," Science, 270:985-988 (1995)					
	Winter and Harris, "Humanized Antibodies," Immunol Today, 14:243-246 (1993)					
	Wright et al., "Genetically engineered antibodies: Progress and prospects," Crit. Reviews in Immunol., 12:125-168 (1992)					
	Wu, "From esoteric theory to therapeutic antibodies." Applied Biochemistry and Biotechnology, 47(2/3):107-118 (1994).					
70	Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," Cancer Res, 57:4036-4041 (1997)					

Examiner	5/200	auno el:	Date Considered	Q	1271	05
Signature i		COUNTY INSIN	Cottolacies			

"EXAMINER: Initial if reference considered, whether or not cluston is in conformance with MPEP 609. Draw time strough cludon if not in conformance and not considere it include copy of this form with next communication to applicant. 1 Applicant's unique clusion designation number (operati), 2 See Kines Codes of USPTO Patent Document, of tww.kitspio.gov or MPEP 801.04. 3 Emer Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precade the serial number of the patent occurrent. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18.1 possible. 6 Applicant is to place a check mark hare if English English Englishes.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless 8 contains a valid OA/B control number.

Substitu	ite for form 1	449/PT	0	Complete if known			
				Application Number	10/776,649		
INFO	RMATIO	N DIS	CLOSURE	Filing Date	February 10, 2004		
STATEMENT BY APPLICANT				First Named Inventor	Hanson		
317	( CIVIDIV )	ייי	LIONITI	Art Unit	1644		
(use	as many sh	eets as	necessary)	Examiner Name	llia I. Ouspenski		
Sheet	18	of	18	Attorney Docket Number	ABX-PF1 DIV2		

	NON PATENT LITERATURE DOCUMENTS					
70	Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," Int Immunol, 8:37-44 (1996)					
	Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," Anti-Cancer Drug Design, 6:539-568 (1991)					
ĪO	Zon et al., "Phosphorothioate oligonucleotides," Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))					

	1.00			Onto	10	/\~	100-
Examiner Signature	Thin	LANDA	12241	Date Considered	9	1271	105

\*EXAMINER: Initial if reference considered, whether or not clacton is in conformance with MPEP 609, Draw tine through clacks if not in conformance and not considered, include copy of this form with next communication to applicant. I Applicant's unique citation designation number (optional). 2 See Nincs Codes of USPTO Patient Documents at www.uspto.gov or MPEP 501,04, 3 Enter Office that issued the document, by the two-table code (WIPO Standard ST2), 4 For Japanese patient documents, this indication of the year of the relay on the Empoure must precede a transfer in mineral of the patient countries. 5 King of documents by the appropriate symbols as indicated on the document wiPO Standard ST.18 il possible. 6 Applicant is to place a check many have if English lenguage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner